CliffBio
small molecule

PROMACTA

ELTROMBOPAG OLAMINE

Loss of exclusivityFebruary 2028latest FDA-listed patent expiry
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand namePROMACTA
Active ingredientELTROMBOPAG OLAMINE
StrengthEQ 75MG ACID
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2009
Marketing statusRX

Listed patents

PatentExpiresType
8071129*PEDFebruary 2028—
8828430*PEDFebruary 2028—
8062665*PEDFebruary 2028—
8052993*PEDFebruary 2028—
8052994*PEDFebruary 2028—
8062665August 2027product
8071129August 2027product
8828430August 2027product
8052993August 2027product
8052994August 2027product
7547719*PEDJanuary 2026—
7547719July 2025substance, product

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PROMACTA patent cliff — loss of exclusivity February 2028 | CliffBio